To determine whether increased Tbx3 would be sufficient to promote MASLD, we generated an AAV8 overexpressing a V5-tagged Tbx3 under the control of TBG, a hepatocyte-specific promoter (AAV8-TBG-V5-TBX3). Here, TBX3 is linked to metabolic dysfunction-associated steatotic liver disease.